European Notebook: Renewed Calls For German Pricing Law Changes, Spain Gauges The Value Of Innovation
German health insurers run a cash surplus in the first quarter; Celesio CEO dismissed; Bayer celebrates 150 years; Spain wants to evaluate value for drug pricing; France's drug spend declines in 2012, and more.
You may also be interested in...
Takeda preps for cost-cutting program; Astellas clears path for Xtandi; and Eisai leans on Belviq in the U.S. with aggressive coverage program.
A clinical trial is expected to start in the U.S. and Europe in 2014 of an individualized approach to developing a cancer vaccine for glioblastoma patients.
Prices may decrease, but at least wider societal benefits are to be included in NICE’s assessment in the U.K.’s new value-based pricing (VBP) scheme for new pharmaceuticals, a change long demanded by critics of the health technology assessment body.